Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY19 is not expected to be complete until June, 2020.

  1. NMDA Receptor Subtype Selective Modualtors as Alzheimer's Disease Therapeutics

    SBC: NEUROP, INC.            Topic: NIA

    DESCRIPTION (provided by applicant): Alzheimer's disease (AD) is a devastating neurodegenerative disorder. One of the few drugs used to treat AD is memantine, which inhibits N-methyl-d-aspartate receptors (NMDARs), glutamate receptor subtypes found at nearly all vertebrate excitatory synapses. NMDARs are critically involved in many aspects of nervous system function, including learning and me ...

    STTR Phase I 2014 Department of Health and Human Services
  2. Enable Early and Sensitive In Vivo Detection of Liver Metastasis by Protein-based

    SBC: INLIGHTA BIOSCIENCES L.L.C.            Topic: NCI

    DESCRIPTION (provided by applicant): The major barriers limiting the application of MRI to detect small liver lesions and metastasis at the early stage and patient selection for targeted therapy based on molecular imaging of disease biomarkers, are due tothe lack of desired MRI contrast agents capable of enhancing the contrast between normal liver tissues and tumors with high relaxivity, tumor tar ...

    STTR Phase I 2014 Department of Health and Human Services
  3. Robotic whole organism HTS platform for drug discovery and development

    SBC: Luminomics Inc.            Topic: NCATS

    DESCRIPTION (provided by applicant): Our goal is to create a compact, affordable, fully automated, screening system for large-scale drug 2 testing in living small animal disease models (e.g., worms, flies, and fish). Modern drug discovery is 3 driven by high-throughput screening (HTS) systems that have the capacity to evaluate large chemical 4 compound 'libraries'. The majority of hits ...

    STTR Phase I 2014 Department of Health and Human Services
  4. High-specificity affinity reagents for the detection of glycan sialylation

    SBC: GLYCOSENSORS AND DIAGNOSTICS, LLC            Topic: 300

    DESCRIPTION provided by applicant Glycans have several distinct properties that make their development as disease biomarkers appealing Firstly their location on cell surfaces makes them the first point of contact for cellular interactions and thus they are crucial in the control of normal metabolic processes and conversely they function as pathogen adhesion receptors Secondly specific gl ...

    STTR Phase I 2015 Department of Health and Human Services
  5. Development of Isotopically Labeled Glycoproteins for use as Internal Standards

    SBC: GlycoScientific, L.L.C.            Topic: 300

    DESCRIPTION provided by applicant The ability to accurately quantitate the glycan chains attached to glycoproteins has wide ranging implications Numerous studies over the past years have demonstrated that abnormal glycosylation occurs in virtually all types of human cancers and demonstrate the potential of using glycan markers in either a diagnostic or a prognostic manner The glycosylatio ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  6. Manufacturing pathogen inactivated platelet lysate to treat corneal inflammation

    SBC: Cambium Medical Technologies LLC            Topic: N

    DESCRIPTION provided by applicant Ocular graft versus host disease O GVHD is a particularly severe and debilitating complication of allogeneic hematopoietic stem cell transplantation HSCT O GVHD develops in of patients with chronic GVHD Currently Restasis cyclosporine A is the only FDA approved prescription topical medication to treat O GVHD In Restasis had sales o ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  7. Selenium-derivatized New Reagents for Nucleic Acid X-ray Crystallography

    SBC: SENA RESEARCH, INC.            Topic: NIEHS

    DESCRIPTION provided by applicant There are growing demands for D structure determination of nucleic acids and their protein complexes for understanding disease molecule level mechanisms and discovering innovative drugs X ray crystallography is one of the most direct and powerful tools for structure determination of these macromolecules and complexes However the crystallization and phase d ...

    STTR Phase II 2015 Department of Health and Human Services
  8. Anti-CXCL13 mAb to mitigate prostate cancer health disparities

    SBC: JYANT Technologies, Inc.            Topic: NIMHD

    DESCRIPTION provided by applicant The most common metastatic site for hormone refractory prostate cancer HRPC PCa is bone While docetaxel can prolong the overall survival in patients with metastatic HRPC current treatments do not provide a cure Further complicating the matter HRPC is a disease that affects a variety of patients differently which can be problematic for physicians to prov ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  9. Galectin 1: A novel small protein therapy for Duchenne muscular dystrophy

    SBC: STRYKAGEN CORPORATION            Topic: NIAMS

    DESCRIPTION provided by applicant Duchenne Muscular Dystrophy DMD is a fatal muscle disease affecting in every male births DMD results from mutations in the gene encoding the dystrophin a kDa scaffolding protein responsible for providing a mechanical link between the muscle fiber actin cytoskeleton and a transmembrane protein complex called the dystrophin associated glycoprotein ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  10. Optimization of an integrin enhancing molecule for the treatment of Duchenne muscular dystrophy

    SBC: STRYKAGEN CORPORATION            Topic: NIAMS

    DESCRIPTION provided by applicant Duchenne muscular dystrophy is caused by mutations in the dystrophin gene resulting in the loss of the dystrophin glycoprotein complex in skeletal muscle Loss of dystrophin results in reduced sarcolemmal integrity progressive muscle damage and compromised muscle function There is currently no cure and limited treatment options for DMD and all affected child ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government